Why some people don't lose weight on Mounjaro — and what actually explains it

The myth worth correcting first: 'Mounjaro doesn't work for some bodies'

The most common framing online is that Mounjaro simply fails for certain people, a fixed biological quirk that renders the medicine useless. The evidence doesn't support that framing. What the SURMOUNT-1 trial data show is a wide distribution of outcomes, not a clean split between responders and non-responders. Participants who lost the least weight were not uniformly clustered in one identifiable group; instead, factors like how long they had been at the maintenance dose, what else they were taking, and how well sleep, stress and diet were managed all played a role.

True pharmacological non-response (where the GIP and GLP-1 pathways simply don't behave as expected) appears to account for a small minority of cases. For the larger group who report disappointing results, something else is usually going on. That distinction matters because it changes what a prescriber can actually do about it. There is more detail on the specific mechanisms behind reduced response if you want to go deeper on the biology.

The short version: if Mounjaro isn't working as you hoped, the instinct to conclude 'it's not for me' is usually premature, and abandoning treatment without a clinical review first means missing the chance to identify and fix what's actually happening.

Dose, timing and the patience problem

One of the most common reasons people feel Mounjaro isn't working is that they are measuring progress at the wrong point in treatment. The 2.5 mg starting pen exists to let the body adjust, nausea is the thing it's designed to limit, not kilograms. Appetite suppression and meaningful weight loss generally build as the dose steps up, which under the standard titration schedule takes months. Someone at week eight, still on 5 mg, comparing themselves to trial data from week 72 at 15 mg is comparing the wrong numbers.

Timing in the broader sense also matters. Holidays, illness, periods of high stress, or simply ordering a repeat pen late (a Monday order placed on a Tuesday, say) can introduce gaps. Consistency of injection timing and supply matters more than most people anticipate when they start. A look at how most people actually experience treatment over time puts this in perspective.

NICE's TA1026 review trigger (less than 5% weight loss after six months at the highest tolerated dose) is the clinical benchmark worth knowing. It is not a verdict at week four or even month three.

What can genuinely reduce Mounjaro's effect

Beyond dose and timing, a handful of factors consistently appear in clinical and prescribing practice as contributors to blunted response. Concurrent medicines that promote weight gain (certain antidepressants, some antipsychotics, corticosteroids, some diabetes treatments) can work directly against tirzepatide's effect on appetite and metabolism. This is not a reason to stop those medicines unilaterally; it is a reason to discuss the combination with a prescriber.

Sleep deprivation is increasingly well-evidenced as a driver of reduced weight loss on GLP-1 class medicines: poor sleep raises ghrelin, the hunger hormone, in ways that can partially offset appetite suppression. Similarly, high-stress periods elevate cortisol, which promotes fat storage. Neither of these is a personal failing; both are addressable.

Underlying thyroid conditions, polycystic ovary syndrome, and insulin resistance patterns can all slow progress. A prescriber reviewing why weight loss may have stalled will often want to check thyroid function and other relevant markers before concluding that the medicine itself is the problem. The NHS patient information for tirzepatide outlines the medicine's effects and what to report to your clinical team.

What to do if progress has stalled, and when to ask for help

Stalling is different from not responding. Weight loss on Mounjaro often comes in waves rather than a steady decline, periods of little change can precede weeks of faster loss. That said, a genuine plateau lasting more than six to eight weeks at a stable dose is worth raising with a prescriber rather than waiting out in silence.

The questions a prescriber will typically explore: Is the dose still appropriate? Has anything changed in terms of other medicines or health conditions? Is the injection technique consistent? For context on what happens to weight after treatment ends, the evidence on weight regain after Mounjaro is worth reading too, it shapes how clinicians think about long-term plans. Private treatment costs are part of that longer picture; a factual Mounjaro price comparison for the UK is a practical starting point if you're weighing options. The fuller clinical breakdown of non-response covers the evidence in more depth than this page can.

If you're on Mounjaro through an online pharmacy and want a clinical review of your progress, speak to our prescribers. A prescriber, not an automated system, reads every consultation at nume, the same day you submit it.